Recruiting Fanconi Anemia Studies in Phoenix
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study...
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascu...
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function...
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioni...
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will...
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity...
The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
To investigate the effect of VTA ablation at the time of LVAD implant to see if it can reduce the incidence of VTA after surgery...
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrah...
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease....
About Fanconi Anemia Clinical Trials in Phoenix
Fanconi anemia is a rare genetic disorder that affects bone marrow, reducing production of all types of blood cells and increasing cancer susceptibility. It is associated with physical abnormalities and organ defects. Treatment includes blood transfusions, growth factors, and stem cell transplant.
There are currently 9 fanconi anemia clinical trials recruiting participants in Phoenix, ARIZONA. These studies are seeking a combined 16,434 participants. Research is being sponsored by Novo Nordisk A/S, Amgen, AstraZeneca and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Fanconi Anemia Clinical Trials in Phoenix — FAQ
Are there fanconi anemia clinical trials in Phoenix?
Yes, there are 9 fanconi anemia clinical trials currently recruiting in Phoenix, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Phoenix?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.
Are clinical trials in Phoenix free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.
What fanconi anemia treatments are being tested?
The 9 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for fanconi anemia.
Data updated March 2, 2026 from ClinicalTrials.gov